Samuele is currently a Professor of Child and Adolescent Psychiatry at the University of Southampton and Honorary Consultant Child and Adolescent Psychiatry for Solent NHS Trust. He is also Adjunct Associate Professor at the New York University (NYU). Samuele’s main research interests are around neurodevelopmental disorders, with a focus on ADHD. He has published more than 200 peer-review papers, including first author papers in prestigious journals such as the New England Journal of Medicine, The Lancet Psychiatry and the American Journal of Psychiatry. He is Deputy Editor for the Journal of the American Academy of Child and Adolescent Psychiatry and sits on the editorial board of other 5 international journals. He is a member of the European ADHD Guidelines Group, as well as of the child and adolescent psychiatry faculty of the European Collegium of Neuropsychopharmacology (and of the British Association of Psychopharmacology-child and adolescent psychiatry module. In 2020, Prof. Cortese was included in the list of the world's most influential researchers of the past decade, demonstrated by the production of multiple highly-cited papers that rank in the top 1% by citations in the field of psychiatry/psychology in 2019 in Web of Science. In 2020 he also ranked #2 worldwide in terms of expertise on Attention-Deficit/Hyperactivity Disorder (ADHD) according to Expertscape.
Marco Solmi and Samuele Cortese review a recent longitudinal study exploring the trajectories of anxiety and depression during the COVID-19 lockdown in England.
Samuele Cortese reports on a recent study of 13-25 year old people with ADHD, which looks at the comparative risk of psychosis during treatment with methylphenidate and amphetamines.
Samuele Cortese is impressed by a recent RCT of QbTest: a computerised test of attention and activity, which can improve diagnostic decision-making in children and young people with suspected ADHD.
Samuele Cortese considers the findings of a recent nationwide self controlled case series study of the cardiovascular safety of methylphenidate use in children and young people with ADHD.
Samuele Cortese publishes his debut Mental Elf blog on a meta-analysis of n-of-1 trials, which shows that amphetamine derivatives and methylphenidate are superior to placebo, in the short term, for paediatric ADHD.
